After selling Morphic Therapeutic to Eli Lilly for $3.2 billion, Praveen Tipirneni is back a year and a half later with a new biotech working in Morphic’s old wheelhouse of inflammatory bowel …
Read More from Endpoints News
Caldera Therapeutics erupts with $112.5M and a China-originated IBD bispecific
